MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 489.9% in May

MetaVia Inc. (NASDAQ:MTVA) was the target of a significant increase in short interest in May. As of May 29th, there was short interest totaling 408,434 shares, an increase of 489.9% from the May 14th total of 69,235 shares. Currently, 8.0% of the company’s shares are short sold. Based on an average daily volume of 21,957,148 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new position in MetaVia stock. Virtu Financial LLC bought a new stake in shares of MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. Institutional investors and hedge funds own 1.37% of the company’s stock.

MetaVia Trading Up 2.6%

Shares of NASDAQ MTVA traded up $0.05 during midday trading on Thursday, hitting $2.01. 467,739 shares of the stock traded hands, compared to its average volume of 11,260,578. MetaVia has a one year low of $0.97 and a one year high of $19.03. The business has a 50 day moving average price of $1.84 and a two-hundred day moving average price of $3.62.

MetaVia (NASDAQ:MTVA) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.03). As a group, equities analysts expect that MetaVia will post -2.78 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have weighed in on MTVA shares. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of MetaVia in a report on Monday, May 18th. Wall Street Zen upgraded MetaVia from a “sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Friday, April 24th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and an average target price of $20.00.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.